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Tumor necrosis factor inhibitors (TNFi) have become the cornerstone for the treatment of rheumatoid arthritis and other
systemic autoimmune conditions. However, these biologic DMARDs can lead to various opportunistic infections such as viral
infection, tuberculosis, and histoplasmosis. Furthermore, these biologics can also cause severe systemic inflammatory reactions
known as hemophagocytosis lymphohistiocytosis (HLH) that can lead to multiorgan failure and high mortality. Due to
overlapping clinical features and time-intensive microbiological culture methods, distinguishing between HLH and opportunistic
infections can be challenging early in the disease course. We present a similar situation with our patient where the patient met the
diagnostic criteria for HLH however was found to have disseminated histoplasmosis.*is case uniquely evaluates the utility of the
HLH diagnostic criteria and hemophagocytosis for accurate diagnosis of HLH.
1. Introduction
Patients with rheumatoid arthritis who are on immuno-
suppressive medications such as tumor necrosis factor in-
hibitors (TNFi) are at increased risk for developing
infections. Fever and cytopenia should warrant a prompt
investigation as the differential diagnosis ranges from self-
limiting viral infections to disseminated invasive infections
such as tuberculosis and histoplasmosis.
2. Case Presentation
A 63-year-old Caucasian female with established seroposi-
tive (+RF, +ACPA) rheumatoid arthritis for 11 years on
treatment with infliximab and methotrexate (MTX; 20mg/
week) presented with a 1.5-month history of fever, cough,
and dyspnea. She was initially suspected to have community-
acquired pneumonia treated with antibiotics and systemic
steroids with transient improvement; however, her symp-
toms recurred. Initial lab tests showed anemia (Hb: 8.8) and
thrombocytopenia (platelet: 51) with an elevated ferritin of
28,000 ng/ml, low complements (C3: 21; C4: <2), low fi-
brinogen, elevated CRP, normal lipids, and mildly elevated
liver enzymes. CT chest was remarkable for subpleural
opacity without parenchymal infiltrates. Her physical ex-
amination demonstrated chronic limited range of motion of
the left wrist and no active synovitis.
Due to significant elevation in ferritin, recurrent fevers,
cytopenias, and failure to respond to antibiotics, secondary
hemophagocytic lymphohistiocytosis (HLH) was suspected,
with possible triggers being RA, immunosuppression, ma-
lignancy, and infection. Additionally, further testing dem-
onstrated an elevated soluble IL-2 receptor (sIL-2) at
7970U/ml (Ref: 45–1105U/ml). Hence, the patient fulfilled 5
out of 8 HLH-2004 diagnostic criteria for HLHwith elevated
ferritin, low fibrinogen, fever, cytopenia (Hb< 9 and low
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platelets), and elevated sIL-2 receptor. She was empirically
started on high-dose systemic glucocorticoids for manage-
ment of HLH; however, she continued to experience re-
current high-grade fever. Due to suspicion for an underlying
infectious etiology of HLH, bone marrow biopsy was per-
formed which revealed hypercellular bone marrow with
multiple fungal elements consistent with histoplasmosis
without evidence of hemophagocytosis. Subsequent urine
and blood cultures confirmed disseminated histoplasmosis.
Antifungal treatment with intravenous amphotericin
was promptly initiated in the hospital; after adequate clinical
response, the patient was transitioned to itraconazole.
Infliximab and MTX were held during antifungal treatment,
and the patient was switched to hydroxychloroquine. Her
infection was under control during her 9 months of follow-
up with infectious disease, and she remained on antifungal
treatment indefinitely.
3. Discussion
Biologic disease-modifying antirheumatic drugs (DMARDs)
have become the cornerstone for treatment of systemic
autoimmune disorders. With the advancement in technol-
ogy and research, new biologics are emerging that help
improve the treatment and prognosis of autoimmune
conditions. However, these great benefits are not without
significant risks. One of the important side effects associated
with the use of biologics is the risk for development of
opportunistic infections (OIs). Different classes of biologics
differ in their ability to cause OIs. Certain tumor necrosis
factor inhibitors (TNFi) such as infliximab and adalimumab
are associated with higher risk of OI compared to etanercept
[1]. According to a recent meta-analysis of RA patients on
biologics, for every 1000 patients treated with biologics, 1.7
patients developed an OI (0.0017%) [2].
TNFi can lead to OIs due to direct inhibition of tumor
necrosis factor (TNF). TNF is essential for the formation of
granuloma and prevention of granulomatous infections such
as tuberculosis and histoplasmosis. Histoplasmosis is the
most common fungal OI with an estimated incidence of
18.78 per 100,000 persons (0.00018%), second only to tu-
berculosis with an incidence of 53.81 per 100,000 (0.00053%)
patients treated with infliximab [3].
Histoplasmosis is a fungal infection that primarily in-
volves the lungs. Symptoms associated with acute pul-
monary histoplasmosis include fever, chills, cough, and
dyspnea that are similar to bacterial pneumonia. Medias-
tinal adenopathy, which is common in histoplasmosis, can
lead to pleuritic chest pain. Once the infection spreads
systemically, it targets several organs including the liver,
spleen, gastrointestinal tract, and bone marrow. Immu-
nocompromised state, due to HIV or anti-TNF therapy,
increases the risk of systemic infection with histoplasmosis
[4]. Approximately 75% of histoplasmosis cases associated
with TNFi have disseminated disease with a mortality rate
of 3.2% [5]. Additional symptoms noted during the dis-
seminated phase include fever, chills, fatigue, weight loss,
and anorexia. Physical examination typically reveals
lymphadenopathy and hepatosplenomegaly. Laboratory
investigations are significant for pancytopenia, trans-
aminitis, hyperbilirubinemia, elevated lactate de-
hydrogenase, and hyperferritinemia [6]. *e diagnosis is
confirmed by urine and serum testing for histoplasma
antigen, as well as cultures from bronchoalveolar lavage
(BAL) for definitive microbial identification and cytopa-
thology [4]. However, these batteries of diagnostic tests are
time- and resource-consuming, and final confirmatory
results are often delayed. Due to clinical symptoms overlap
of disseminated histoplasmosis with hemophagocytic
lymphohistiocytosis (HLH), timely additional workup is
needed in suspected cases of HLH to distinguish between
the two, as the mortality associated with untreated HLH
can exceed 50% [7].
HLH should be considered in any patient with per-
sistent fever, cytopenia, transaminitis, and hyper-
ferritinemia [8]. *ese findings can overlap with those of
invasive histoplasmosis. RA patients on TNFi are at risk for
HLH [9]; however, there are no reported cases of HLH in
RA patients not on biologic DMARD. In contrast, both
pulmonary histoplasmosis and disseminated histoplas-
mosis have been reported in RA patients irrespective of
TNFi use [10]. Interestingly, there have been several reports
of histoplasmosis associated HLH infection dating back to
1993 [11].
HLH is characterized by widespread multiorgan in-
flammation that involves prolonged activation of antigen
presenting cells (i.e., macrophages and histiocytes) and
CD8+ Tcells, in response to an antigen trigger. Natural killer
(NK) cells, which function to attenuate the inflammatory
signal, are found to be functionally deficient in HLH [12].
*e prolonged activation leads to excessive formation of
cytokines (“hypercytokinemia”) and multiorgan failure [12].
HLH is diagnosed using the HLH-2004 diagnostic criteria.
Traditionally, HLH was classified into primary form (usually
in kids; documented genetic changes and abnormal function
of NK and cytotoxic Tcells) and secondary form, HLHmostly
seen in adults (HLH features in the presence of a trigger such
as infection, without the genetic changes). However, the ge-
netic changes can be seen in adults as well, and thus, primary
and secondary forms of designations have now been corrected
to “genetic” and “acquired” forms of HLH [13].
HLH can be diagnosed either with
(1) genetic testing to check for molecular arrangement
consistent with primary HLH or
(2) 5 out of 8 of the following findings [14]:
(i) Fever
(ii) Splenomegaly
(iii) Cytopenia: affecting 2 of 3 cell lines in the pe-
ripheral blood (hemoglobin in adults<10mg/dL,
platelets <100∗109/L, and neutrophils 1∗ 109/L)
(iv) Hypertriglyceridemia (≥265mg/dl) and
hypofibrinogenemia (<1.5 g/L)
(v) Hemophagocytosis in bone marrow, liver, or
spleen with no evidence of malignancy
(vi) Absence of or low natural killer (NK) cell
activity (local lab reference)
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(vii) Ferritin> 500 microgram/L
(viii) Soluble CD 25 (i.e., soluble IL-2 receptor)≥
2400U/ml
Hemophagocytosis on bone marrow biopsy is an im-
portant feature of HLH and considered the gold standard for
diagnosis. In hemophagocytosis, erythrocytes, leukocytes,
thrombocytes, and their precursors are engulfed by mac-
rophages [15]. In addition to HLH, hemophagocytosis can
be seen on tissue biopsy in the setting of infection, bone
marrow hyperplasia, ineffective hematopoiesis, major sur-
gery, blood transfusion, and chemotherapy. *ere is an
ongoing debate regarding the role of hemophagocytosis in
the diagnosis of HLH. A study evaluating 80 bone marrow
biopsies with hemophagocytosis concluded that pancyto-
penia and high-grade hemophagocytosis (defined as severe
>5 histiocytes with hemophagocytosis/slide) may help dis-
tinguish between HLH and non-HLH etiologies [16]. In
contrast, another recent study analyzing 64 bone marrow
biopsies from 58 patients concluded that hemophagocytosis
does not reliably predict HLH [17].
4. Conclusion
*is patient met the diagnostic criteria for HLH; however,
the bone marrow biopsy did not show hemophagocytosis.
Her treatment for HLH was initiated with immunosup-
pression without any response. Subsequently, she was
switched to antifungal therapy for disseminated histoplas-
mosis and showed excellent response. In the current di-
agnostic criteria of HLH, presence or absence of
hemophagocytosis does not mandate or refute the diagnosis
nor does it have any prognostic significance. However, this
case was successfully treated with antifungal alone without
the need for additional immunosuppression. It is worth
exploring whether the absence of hemophagocytosis in HLH
has a clinical/prognostic significance and would warrant a
different treatment strategy, as in this case.
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